Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113294 | 0.82 | CRHR1 (0.41) | CRHR1SRD5A1TRAP1 | |
| SCHEMBL5100161 | 0.82 | CRHR1 (0.47) | CRHR1SRD5A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5106990 | 0.80 | CRHR1 (0.51) | CRHR1SMN1; SMN2P2RX7 | |
| SCHEMBL5103520 | 0.78 | CRHR1 (0.42) | CRHR1SRD5A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2190889 | 0.76 | CRHR1 (0.54) | CRHR1SRD5A1TRAP1TP53MAPT | |
| SCHEMBL5806699 | 0.76 | CRHR1 (0.40) | CRHR1TP53MAPTSMN1; SMN2HTR1A | |
| SCHEMBL5055712 | 0.75 | CRHR1 (0.40) | CRHR1TP53MAPTSMN1; SMN2PHGDH | |
| SCHEMBL5051889 | 0.72 | CRHR1 (0.37) | CRHR1RBP4 | |
| SCHEMBL5055764 | 0.70 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL5112592 | 0.69 | CRHR1 (0.51) | CRHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235871-A1 | Crf receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885SRD5A1 763/4885TRAP1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.